文献速递头颈与中枢神经肿瘤

PET-CT引导的局部晚期头颈癌管理长期成本效果分析

Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer.
PubMed 文献 · Eur J Cancer · 2017-09-04

基于英国一项大型临床试验数据,采用Markov模型模拟终身成本效果,评估PET-CT引导的颈清扫管理相较于计划性颈清扫的成本效果。结果显示PET-CT管理人均终身节省£1485并获得额外0.13 QALYs,在£20,000/QALY阈值下具有75%概率为成本效果;采用更广泛NHS和PSS视角时平均节省£700,81%概率为成本效果。

要点

  • PET-CT引导管理相比计划性颈清扫人均终身节省£1485且增加0.13 QALYs
  • 在£20,000/QALY支付阈值下PET-CT管理有75%概率具有成本效果
  • 采用NHS和PSS视角时PET-CT管理平均节省£700,81%概率具有成本效果

核心结论

  • PET-CT引导的局部晚期头颈癌颈清扫管理从英国二级医疗视角看长期具有成本效果,支持广泛采用。

研究设计与样本

  • 基于近期英国大型临床试验数据,初始6个月成本和健康结局取自试验数据,后续复发和死亡率用新构建的Markov模型模拟,健康效益以QALYs衡量,成本以2015年英镑报告。
  • 模型参数来自试验数据和已发表文献,并进行了敏感性分析评估不确定性和更广泛NHS及PSS成本的影响。

主要发现

  • PET-CT管理人均终身成本节省£1485,并额外获得0.13 QALYs。
  • 在每额外QALY支付意愿£20,000阈值下,PET-CT具有成本效果的概率为75%,且在大多数敏感性分析中结果保持成本效果。
  • 采用更广泛NHS和PSS视角时,PET-CT管理平均节省£700,具有成本效果的概率为81%。

关键数值与推荐

  • 支付意愿阈值为每额外QALY £20,000。
  • PET-CT管理人均终身成本节省£1485,额外获得0.13 QALYs。
  • 在£20,000/QALY阈值下PET-CT成本效果概率为75%。
  • NHS和PSS视角下平均节省£700,成本效果概率为81%。

临床怎么用

  • 分析结果表明PET-CT引导管理长期具有成本效果,支持广泛采用。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A recent large United Kingdom (UK) clinical trial demonstrated that positron-emission tomography-computed tomography (PET-CT)-guided administration of neck dissection (ND) in patients with advanced head and neck cancer after primary chemo-radiotherapy treatment produces similar survival outcomes to planned ND (standard care) and is cost-effective over a short-term horizon. Further assessment of long-term outcomes is required to inform a robust adoption decision. Here we present results of a lifetime cost-effectiveness analysis of PET-CT-guided management from a UK secondary care perspective. METHODS: Initial 6-month cost and health outcomes were derived from trial data; subsequent incidence of recurrence and mortality was simulated using a de novo Markov model. Health benefit was measured in quality-adjusted life years (QALYs) and costs reported in 2015 British pounds. Model parameters were derived from trial data and published literature. Sensitivity analyses were conducted to assess the impact of uncertainty and broader National Health Service (NHS) and personal social services (PSS) costs on the results. RESULTS: PET-CT management produced an average per-person lifetime cost saving of £1485 and an additional 0.13 QALYs. At a £20,000 willingness-to-pay per additional QALY threshold, there was a 75% probability that PET-CT was cost-effective, and the results remained cost-effective over the majority of sensitivity analyses. When adopting a broader NHS and PSS perspective, PET-CT management produced an average saving of £700 and had an 81% probability of being cost-effective. CONCLUSIONS: This analysis indicates that PET-CT-guided management is cost-effective in the long-term and supports the case for wide-scale adoption.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Smith AF, Hall PS, Hulme CT, et al. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. Eur J Cancer. 2017. PMID: 28881249. doi:10.1016/j.ejca.2017.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。